-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Genmab and AbbVie announced that the results of the phase 1/2 clinical trial EPCORE NHL-1 of the CD3/D20 bispecific antibody epcoritamab, which is under development, were published in the well-known academic journal "The Lancet"
.
The trial evaluated the safety and efficacy of the therapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL)
A bispecific antibody is an antibody molecule that can specifically bind to two different antigens
.
Epcoritamab is a bispecific T cell redirection antibody
The dose-escalation part of the open-label, multicenter EPCORE NHL-1 trial was carried out in 68 patients with relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma (B-NHL), including diffuse large B-cell lymphoma Tumors and follicular lymphoma
.
The test results showed that no dose-limiting toxicity was observed during the dose escalation process, and the recommended dose (RP2D) for the phase 2 clinical trial was determined to be 48 mg
.
Common adverse events (AE) in patients with relapsed/refractory DLCBL were fever (69%), mainly related to cytokine release syndrome (CRS) (59%, all grades 1-2) and injection site reactions (47%) , All are level 1) related
In patients with relapsed/refractory DLCBL who received RP2D therapy (n=8), the preliminary efficacy results reported in the trial showed that the patients achieved an overall response rate (ORR) of 88% and a complete response (CR) of 38%
.
Secondly, patients (n=22) who received 12-60 mg epcoritamab achieved 68% ORR and 45% CR
Reference materials:
[1] Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet.
(The original text has been deleted)
